Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AK BioPharm
Ulsan, Ulsan, South Koreaakb.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AK BioPharm is a world leader in manufacturing high-purity Omega‑3 active pharmaceutical ingredients (APIs), focusing on EPA and DHA separation and concentration up to 97% using proprietary Vacuum Fraction Distillation and HPLC technologies under GMP regulations. Their APIs have received regulatory approvals from KFDA, PMDA, and DMF filings for use in pharmaceuticals and dietary supplements[1][2][3][5].
- Therapeutic areas
- Metabolic Disorders
- Modalities
- Small moleculeFish oil-derived biologicOmega fatty acid derivative
- Industry
- Contract Manufacturing Organization
02
Partnerships
Previously partnered with Maruha Nichiro Corporation of Japan until September 2022[5].
Beyond the preview
Go deeper on AK BioPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK BioPharm.